In Dutch primary care, approximately a quarter of patients with T2DM with intermediate or long-acting insulins were prescribed the newer long-acting insulins insulin degludec or insulin glargine 300 U/ml, in spite of the current guideline advising other intermediate or long-acting insulins.5 Practice variation was extensive and largely remained after correction for patient and practice characteristics. Here, INS is linked to type 2 diabetes mellitus.